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AbstrACt
background The clinical response to immune checkpoint 
inhibitors (ICIs) in only part of the treated patients, in 
conjunction with the potentially serious side effects 
associated with this type of therapy, has emphasized the 
need to identify biomarkers to select patients who may 
benefit from ICI treatment. The aim of our study was to test 
human leukocyte antigen (HLA) class I and II expression in 
melanoma metastases as potential biomarkers of response 
to ipilimumab and survival in patients with metastatic 
melanoma, since these molecules play a crucial role in the 
interactions of malignant cells with host’s immune system.
Materials and methods HLA class I and II antigen 
expression level in pretreatment surgical tissue samples 
(50 lymph node and 35 cutaneous or subcutaneous 
metastases) from 30 patients was analyzed by 
immunohistochemical staining with monoclonal antibodies. 
Expression levels were correlated to intratumoral density 
of lymphocytes expressing cluster of differentiation 
(CD)8, CD45RO, CD4, forkhead box P3 (FOXP3) and/
or programmed cell death protein 1 (PD-1), to clinical 
response to treatment, and to patients’ survival.
results HLA class I antigen expression level in lymph 
node metastases, but not in cutaneous or subcutaneous 
metastases was significantly correlated to density of CD8+ 
and CD45RO+ T cells and of lymphocytes expressing PD-1, 
as well as to clinical response and to patients’ survival.
Conclusions Our results corroborate the role of HLA class 
I expression level (alone or in combination with T- cell 
density values) as a predictive biomarker of response to 
ipilimumab in patients with melanoma. In addition, our 
results show that this association is influenced by the 
anatomic site of the metastasis used to measure the HLA 
class I antigen expression level.
IntroduCtIon
Immunotherapy with monoclonal antibodies 
(mAbs) targeting immune checkpoints 
has been shown to induce durable clinical 
responses in an increasing number of cancer 
types. However, only a percentage (between 
about 10% and 40% depending on tumor 
type when used as monotherapy) of the 
treated patients benefits from this therapy.1 
Its efficacy will be greatly increased by the 
identification of biomarkers able to predict 
clinical response to therapy and by the devel-
opment of strategies to counteract resistance 
mechanisms to immune checkpoint inhibi-
tors (ICIs).2 3 The available evidence strongly 
suggests that ICI- based therapy is effective in 
patients bearing tumors with high mutational 
burden (therefore containing a large number 
of potential neoantigens), and showing high 
immunological activity (immune cell infiltra-
tion, immune response- related gene expres-
sion).1 3 4
Effective antitumor immune response 
is dependent on the recognition of tumor 
antigens by antigen- specific T lymphocytes 
in the context of human leukocyte antigen 
(HLA) class I molecules. To this end, expres-
sion of a fully functional HLA class I antigen 
processing machinery (APM) by tumor cells 
is crucial for the recognition and destruction 
of tumor cells by cognate cluster of differ-
entiation (CD)8+ T cells. Defects in HLA 
class I APM component expression have 
been reported to be associated with disease 
progression and poor prognosis in several 
cancer types.5 6 Moreover, functional HLA 
class I APM is expected to be crucial for the 
success of T- cell- based immunotherapies. 
Mutation or loss of heterozygosity of β2- mi-
croglobulin (β2M), an essential component 
of the HLA class I complex, was identified as 
a mechanism of primary and acquired resis-
tance to cytotoxic T lymphocyte- associated 
antigen 4 (CTLA-4) and programmed cell 
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other types of T- cell- based immunotherapies.10 However, 
structural mutations leading to defective HLA class I APM 
component expression and/or function have a frequency 
of less than 10%.6 Defects of HLA class I APM compo-
nent expression are most frequently caused by epigen-
etic mechanisms.6 11 Nevertheless, the association of HLA 
class I protein expression with response to ICI therapyi 
has been investigated only to a limited extent,12 and only 
two studies have addressed the association between HLA 
class II antigen expression on tumor cells and response 
to ICI.12 13
In a recent study we examined infiltration of 11 
immune cell types in pretreatment surgical samples of 
patients with metastatic melanoma treated with ipilim-
umab. We found a positive association between immune 
cell density in lymph node metastases and response to ICI 
therapy for several cell types, including CD4+ and CD8+ T 
lymphocytes, forkhead box P3 (FOXP3+) cells, CD20+ B 
lymphocytes, NKp46+ NK (natural killer) cells, and cells 
expressing the activation markers CD134 or CD137.14 The 
aim of the present study was to analyze HLA class I and 
class II expression in the set of samples we had previously 
analyzed for immune cell infiltration, to correlate it with 
T- cell infiltration and to assess its value as a biomarker of 
clinical response to ipilimumab therapy and survival in 
patients with metastatic melanoma.
MAterIAls And Methods
tumor samples
Archived paraffin blocks of pretreatment surgical tissue 
samples (50 lymph node and 35 cutaneous/subcuta-
neous metastases) were collected from 30 patients with 
metastatic melanoma who received ipilimumab treat-
ment between 2010 and 2014. The clinical characteris-
tics of this patient cohort, previously used to assess the 
predictive value of tumor- infiltrating immune cells, have 
been described in detail elsewhere.14 Eighteen patients 
received ipilimumab treatment in the Expanded Access 
Program, three patients after drug commercialization, 
and nine patients participated in the CA-184-169 trial. 
Sample collection was restricted to metastases surgically 
removed within 1 year before ipilimumab treatment to 
reduce potential changes in immune status during the 
time elapsed between surgery and ipilimumab therapy.
Monoclonal antibodies
The mouse mAb HCA2, recognizing β2M- free HLA- A 
(excluding HLA- A24), HLA- B7301 and HLA- G heavy 
chains, mAb HC10, recognizing β2M- free HLA- A3, HLA- 
A10, HLA- A28, HLA- A29, HLA- A30, HLA- A31, HLA- A32, 
HLA- A33, HLA- B (excluding HLA- B5702, HLA- B5804 
i Note added in proof: a recent paper (Such L et al: Targeting 
the innate immunoreceptor RIG- I overcomes melanoma- 
intrinsic resistance to T cell immunotherapy, J Clin Invest, in 
press) demonstrated an association between HLA- I APM gene 
downregulation at the transcriptional level and ICB resistance 
in patients with melanoma.
and HLA- B73) and HLA- C heavy chains, β2M- specific 
mAb NAMB1 and mAb LGII-612.14 recognizing the β 
chains of HLA- DR, DQ, DP antigens were developed and 
characterized as described.15–17 The mAb EMR8-5, recog-
nizing an epitope expressed by HLA- A, B, and C heavy 
chains, was purchased from Abcam.
Immunohistochemical staining and evaluation
Tissue sections were stained with mAbs, using stan-
dard methodology previously described.14 Staining was 
detected using the SS One- Step Polymer- HRP IHC Detec-
tion System (BioGenex) and 3- amino-9- ethylcarbazole 
(Vector Laboratories). Sections were counterstained with 
hematoxylin. Staining with HLA class I subunit- specific 
mAbs was scored as 0, 1, and 2 when the percentage of 
stained melanoma cells was <25%, 25%–75%, and >75%, 
respectively, based on the criteria established by the 12th 
International Histocompatibility Workshop (1996). In 
the case of HLA- DR, DQ, DP, the percentage of the area 
displaying positive tumor cell staining was determined in 
the metastases. For patients with more than one metas-
tasis available, the average scores were calculated for each 
marker. Evaluation was done independently by two inves-
tigators who were blinded to the clinical information, and 
the mean value of their separate scores was used for the 
analysis. The proportion of patients with high HLA class 
I expression on melanoma cells was also calculated, using 
cut- off values based on the median of each marker in the 
whole patient cohort, with minor adjustment for better 
discriminating power in the case of NAMB1 (scores of 1.5 
for the epitopes recognized by mAbs HCA2 and HC10, 
1.9 for EMR8-5, and 1.2 for NAMB1). Cut- off values of 1% 
and 10% were used for the epitope recognized by mAb 
LGII-612.14.
statistical analysis
Associations between the proportion of patients with 
high HLA expression and response to ipilimumab were 
calculated using the χ2 test. Correlation of HLA expres-
sion levels with immune cell infiltration was evaluated 
using the Pearson test; immune cell density values (cell 
number/mm2) have been derived from our previous 
study.14 To assess intrapatient heterogeneity, coefficient of 
variation was calculated [CV=(SD/mean)×100]. Analysis 
of survival, evaluated from start of ipilimumab treatment, 
was performed by the Kaplan- Meier method, using the 
generalized Wilcoxon test. Cox regression analyses were 
performed using mean HLA expression scores and other 
clinicopathological variables. Statistics were calculated 
using the BMDP Statistical Software Package.
results
Surgically removed lymph node and cutaneous/subcu-
taneous melanoma metastases were analyzed for HLA 
expression. There was no difference between lymph node 
and cutaneous/subcutaneous metastases in HLA class I 
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Figure 1 Immunohistochemical staining of melanoma metastases with human leukocyte antigen- specific monoclonal 
antibodies (mAbs) (3- amino-9- ethylcarbazole, red). Staining with (A–C) mAb HC10 (scores 2, 1, and 0, respectively); (D) mAb 
HCA2 (score 2); (E) mAb EMR8-5 (score 2); (F) mAb NAMB1 (score 2); (G) mAb LGII-612.14 (evaluated as 83% expression); and 
(H, I) heterogeneous staining with mAb LGII-612.14 (H) and mAb HC10 (I) detected mainly in tumor cells at the margin of the 
metastases. β2M, β2- microglobulin.
(mean±SD, 1.3±0.8 vs 1.3±0.7), HC10 (1.3±0.7 vs 1.2±0.8), 
EMR8-5 (1.5±0.7 vs 1.6±0.6), or NAMB1 (1.2±0.8 vs 
1.1±0.7). In the case of HLA class II expression, with the 
exception of one patient whose lymph node metastases 
showed high percentage of stained melanoma cells (43% 
on average, range 3%–86%; figure 1G), the majority 
(62%) of metastases were not stained by mAb LGII-
612.14, irrespective of anatomic site. At least 1% of mela-
noma cells were stained by mAb LGII-612.14 in 41% of 
nodal and in 34% of cutaneous/subcutaneous metastases, 
while more than 10% of cells were stained in 16% and 
6%, respectively. In many cases showing heterogeneous 
staining for HLA class I or class II, higher labeling was 
observed in tumor cells in the proximity of inflammatory 
cells at the margin of the metastases; this finding is consis-
tent with locally induced HLA expression (figure 1H,I). 
In the 18 patients with more than one metastasis analyzed 
(median of 4 (range 2–9) metastases), the average CVs 
indicating intrapatient heterogeneity were 32.8%, 42.0%, 
29.9%, 41.1%, and 37.3% for staining by mAbs HCA2, 
HC10, EMR8-5, NAMB1, and LGII-612.14, respectively.
HLA class I and class II expression levels in lymph node 
metastases showed positive correlation with intratumoral 
density of CD8+ and CD45RO+ T cells (table 1), but not 
with that of CD4+ or FOXP3+ cells (not shown). Further-
more, HLA expression was significantly correlated with 
the density of lymphocytes expressing PD-1 (table 1). On 
the other hand, in subcutaneous/cutaneous metastases 
HLA class I expression level was not correlated with the 
extent of T- cell infiltration, while HLA class II expres-
sion was correlated with CD8+, CD45RO+, and PD-1+ cell 
density (table 1).
Patients were divided into two groups according to the 
clinical response to ipilimumab therapy: “responders,” 
including 11 patients displaying complete or partial 
response, or stable disease for more than 6 months, and 
“non- responders,” including 19 patients with disease 
progression or stable disease for ≤6 months. The propor-
tion of patients with high mean tumor cell HLA class I 
scores in lymph node metastases was significantly higher 
in “responders” compared with “non- responders,” when 
results of staining with mAb EMR8-5 were analyzed. A 
similar difference was observed for the results obtained 
with mAb HC10 and NAMB1, although the difference did 
not reach the level of statistical significance (table 2). The 
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 r  P value  r P value  r P value
Lymph node metastases 
(n=50)
HC10 0.4493 <0.001 0.3913 <0.01 0.4111 <0.01
HCA2* 0.5092 <0.001 0.3542 <0.05 0.5121 <0.001
EMR8-5 0.3710 <0.01 0.3427 <0.02 0.3453 <0.02
Anti-β2M 0.3339 <0.02 0.3204 <0.05 0.3145 <0.05
Anti- HLA- DR, DQ, DP 0.4251 <0.01 0.3021 <0.05 0.4335 <0.01
Cutaneous/subcutaneous 
metastases (n=35)
HC10 −0.0523 NS −0.0698 NS −0.1869 NS
HCA2 0.1724 NS 0.1619 NS 0.0612 NS
EMR8-5 −0.1794 NS −0.2340 NS −0.1674 NS
Anti-β2M −0.0299 NS −0.0205 NS −0.1067 NS
Anti- HLA- DR, DQ, DP 0.6440 <0.001 0.3734 <0.05 0.5217 <0.001
Significant correlations are shown in bold.
*There were two patients (12 lymph node metastases) where HCA2 could not be evaluated because of negativity of normal cells.
 
CD, cluster of differentiation; HLA, human leukocyte antigen; β2M, β2- microglobulin; NS, not significant; PD-1, programmed cell death 
protein 1; r, Pearson correlation coefficient.
from the one with partial response displayed high reac-
tivity with mAb HC10. In contrast, the frequency of metas-
tases with high reactivity with mAb HC10 was significantly 
lower in patients with stable or progressive disease; high 
staining was found in only 6 of the 15 patients. Similar 
results were obtained with mAb EMR8-5, although the 
difference was not statistically significant (table 2). No 
differences in HLA class I expression were found between 
“responders” and “non- responders” when cutaneous/
subcutaneous metastases were analyzed (table 2). Anal-
ysis of the reactivity pattern of the metastases with the 
four HLA class I subunit- specific mAbs showed that the 
number of metastases strongly stained by most of the mAbs 
tested was higher in the cohort of patients with complete 
or partial response compared with those with stable or 
progressive disease following ipilimumab treatment. This 
difference was observed when lymph node metastases 
and cutaneous/subcutaneous metastases were analyzed 
as individual groups or as a whole group. In contrast, 
HLA class II expression showed no association with treat-
ment response in any of the patient groups studied. Eval-
uation of HLA class I or class II scores in combination 
with density values of CD8+ or CD45RO+ T cells did not 
increase the predictive effect of CD8+ or CD45RO+ T- cell 
density alone, described in our previous paper.14
Overall survival by Kaplan- Meier curve was significantly 
associated with HLA class I expression level in lymph node 
metastases but not with that in cutaneous/subcutaneous 
metastases (figure 2). Prognostic correlates of HLA class 
I expression scores evaluated as continuous variables, 
together with patients’ age and gender, Eastern Coop-
erative Oncology Group (ECOG) status, lactate dehy-
drogenase (LDH) level, number of organs involved and 
disease stage, were also analyzed using Cox’s proportional 
hazards model. In univariate analysis evaluating lymph 
node metastatic cases, scores obtained with mAb HCA2 
(p=0.0456) and with mAb HC10 (p=0.0210), besides 
ECOG status (p=0.0009) and LDH (p=0.0227) were 
significantly associated with overall survival. In multivar-
iate analysis, only ECOG status was significantly (p=0.001) 
associated with survival. When evaluated in cutaneous/
subcutaneous or in all metastases analyzed, HLA class I 
expression was not significantly associated with survival 
in either univariate or multivariate analysis; in the latter 
groups only LDH level was an independent biomarker 
of survival (p=0.001 and p=0.000, respectively). When 
the combined score obtained with the four HLA class I 
subunit- specific mAbs was included in the analysis instead 
of the scores obtained with each mAb, a concordant high 
expression in the lymph node metastases of the majority 
of the epitopes analyzed was significantly (p=0.0017) 
associated with survival in univariate, but not in multivar-
iate analysis. The same association was found when the 
patients were analyzed as a whole group (p=0.0240). In 
contrast, HLA class II expression was not significantly 
associated with survival either in univariate or in multivar-
iate analysis. Evaluation of HLA class I scores in combina-
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SD ≤6 months P value CR+PR PD+SD P value
Lymph node metastases (no of patients: 19)
HC10 5/6 (83%) 5/13 (38%) 0.0686 4/4 (100%) 6/15 (40%) 0.0327
HCA2* 4/5 (80%) 6/12 (50%) 0.2521 3/3 (100%) 7/14 (50%) 0.1103
EMR8-5 6/6 (100%) 6/13 (46%) 0.0237 4/4 (100%) 8/15 (53%) 0.0856
β2M 5/6 (83%) 5/13 (38%) 0.0686 3/4 (75%) 7/15 (47%) 0.3133
Low expression with 
≤1 Abs
5/6 (83%) 5/13 (38%) 0.0686 4/4 (100%) 6/15 (40%) 0.0327
Cutaneous/subcutaneous metastases (no of patients: 20)
HC10 6/8 (75%) 7/12 (58%) 0.4439 3/4 (75%) 10/16 (62%) 0.6392
HCA2 5/8 (62%) 6/12 (50%) 0.5820 3/4 (75%) 8/16 (50%) 0.3687
EMR8-5 5/8 (62%) 7/12 (58%) 0.8522 4/4 (100%) 8/16 (50%) 0.0679
β2M 6/8 (75%) 8/12 (67%) 0.6903 4/4 (100%) 10/16 (62%) 0.1432
Low expression with 
≤1 Abs
5/8 (62%) 5/12 (42%) 0.3613 4/4 (100%) 6/16 (37%) 0.0253
All cases (no of patients: 30)
HC10 8/11 (73%) 9/19 (47%) 0.1768 5/6 (83%) 12/24 (50%) 0.1405
HCA2* 6/10 (60%) 7/18 (39%) 0.2831 4/5 (80%) 9/23 (39%) 0.0968
EMR8-5 8/11 (73%) 9/19 (47%) 0.1768 6/6 (100%) 11/24 (46%) 0.0166
β2M 8/11 (73%) 10/19 (53%) 0.2789 5/6 (83%) 13/24 (54%) 0.1921
Low expression with 
≤1 Abs
7/11 (64%) 7/19 (37%) 0.1563 6/6 (100%) 8/24 (33%) 0.0034
Significant differences are shown in bold.
*Staining with HCA2 could not be evaluated in two patients because of negativity of normal cells.
Abs, antibodies; CR, complete response; HLA, human leukocyte antigen; β2M, β2- microglobulin; PD, progressive disease; PR, partial 
response; SD, stable disease.
node metastases using univariate Cox regression analysis 
revealed that high HLA class I expression combined with 
high T- cell density was associated with markedly better 
survival compared with all other cases analyzed together 
(p=0.0001, p=0.0021, p=0.0033, p=0.0002, p=0.0053, and 
p=0.0012 in the case of CD45RO/HC10, CD45RO/HCA2, 
CD45RO/EMR8-5, CD8/HC10, CD8/HCA2, and CD8/
EMR8-5, respectively). High CD45RO/HC10 combina-
tion proved to be a significant independent predictor of 
good prognosis in multivariate analysis (p=0.000). In the 
case of cutaneous/subcutaneous metastases, CD45RO/
EMR8-5 and CD45RO/NAMB1 combinations proved to 
be significant factors (both p=0.0128) in univariate but 
not in multivariate analysis.
dIsCussIon
The efficacy of ICI- based therapies in only a proportion 
of treated patients has been a major stimulus to search 
for biomarkers which could identify patients likely to 
benefit from this therapy. A number of variables have 
been tested. Among them, programmed death ligand 
1 (PD- L1) expression in tumors has been approved by 
Food and Drug Administration as a companion diag-
nostic marker to select patients to be treated with PD-1/
PD- L1 inhibitors.18 Moreover, emerging data indicate the 
importance of tumor- derived and host- derived factors 
involved in antitumor immune reactions, such as neoan-
tigen expression level, systemic and local immune activity, 
in influencing the clinical efficacy of ICIs.1 3 4 However, 
limited attention has been paid to the value of HLA class 
I expression level on tumor cells as a biomarker to predict 
clinical responses to ICI- based therapy. This is surprising 
in light of the crucial role played by HLA class I antigens 
in the presentation of tumor antigen- derived peptides to 
cognate cytotoxic T cells unleashed by ICI and the rela-
tively high frequency of defects in HLA class I expression 
by tumor cells.5 6 11
The paucity of information in the literature about 
the role of HLA class I defects in the clinical response 
to ICI- based therapy has prompted us to investigate the 
association between HLA class I expression in metastases 
and clinical responses in a cohort of patients treated with 
ipilimumab. To the best of our knowledge, this associa-
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Figure 2 Kaplan- Meier curves of overall survival for patients with melanoma subdivided according to staining with human 
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study and ours share some similarities, but display also 
some differences. Both studies used the mAb EMR8-5 
recognizing an epitope shared by the gene products of 
HLA- A, B, and C loci. Both have reached the conclusion 
that HLA class I expression level in metastases is signifi-
cantly associated with clinical response to ipilimumab. 
In addition, our study which has used also HLA class I 
subunit- specific mAbs suggests that the expression level 
of HLA- B and C antigens may play a more important role 
than that of HLA- A antigens in the clinical response to 
anti- CTLA-4 mAb therapy. Provided that this difference 
is not caused by the distinct characteristics of the two 
mAbs used to measure the expression level of the gene 
products of HLA- A and of HLA- B and C loci, it may 
reflect the different characteristics of the tumor antigens 
presented by HLA- A antigens and by HLA- B and C anti-
gens including but not limited to their range of specificity 
and to their immunogenicity.
An additional difference between our study and that 
of Rodig et al12 is that in the latter study biopsy samples 
obtained from metastases in several distinct anatomic 
sites were included. In contrast, we evaluated whole 
tumor sections (generally representing larger portions 
of the tumors compared with biopsies), from surgical 
samples of several metastases per patient when avail-
able, to reduce the confounding effect of heterogeneous 
expression of HLA antigens. Moreover, we analyzed 
only metastatic samples derived from two anatomic 
sites, lymph nodes and cutaneous/subcutaneous tissues. 
Our study has shown that HLA class I expression level 
in lymph node metastases, but not that in cutaneous/
subcutaneous ones, is associated with clinical response 
and survival of patients treated with ipilimumab. Tumor 
cell expression of HLA class II did not show correlation 
with outcome of ipilimumab therapy, similarly to earlier 
studies where melanoma- specific HLA class II expression 
predicted response to anti- PD-1, but not to anti- CTLA-4 
treatment.12 13
Our data are compatible with the possibility that epigen-
etic changes induced by the tumor microenvironment in 
HLA class I antigen expression on melanoma cells have a 
major impact on its role as a biomarker of clinical response 
to ICI- based therapy. In our previous investigation on the 
same patient cohort,14 we found more pronounced effect 
of immune cell infiltration in nodal versus cutaneous/
subcutaneous metastases on the outcome of ipilimumab 
therapy. Likewise, in the present study response to ipilim-
umab and survival were significantly associated with HLA 
class I expression, only when lymph node metastases were 
analyzed. Also, HLA class I expression level in lymph 
node metastases, but not in cutaneous or subcutaneous 
ones was significantly correlated to T- cell density. These 
results suggest different biology of metastases of lymph 
nodes versus non- lymphoid organs, presumably due to 
the distinct immune milieu. Tissue- specific differences 
in the tumor microenvironment may influence growth 
and progression of tumors as well as their therapeutic 
sensitivity.19–21 Variation in immune cell infiltration and 
antigen expression according to metastatic site has been 
reported in melanoma and other tumor types.20–23 Immu-
notherapy biomarker studies, however, generally do not 
take into consideration anatomic site when selecting 
lesions for the investigations, although it could reduce 
variability of the results.24
An interesting finding of our study was that analyzing 
tumor cell HLA class I expression in combination with 
CD8+ or CD45RO+ T- cell density values showed higher 
potency to predict survival in comparison with either 
HLA scores or T- cell density values alone (described 
here and in our previous report14). It calls attention to 
the usefulness of multiple immunohistochemistry (IHC) 
assays, which was proved the strongest predictor of check-
point blockade efficacy in the case of PD-1/PD- L1 inhibi-
tors according to a recent meta- analysis.25
Our study has some limitations, mainly because of its 
retrospective nature. Furthermore, the number of cases 
that could be included in the analysis was limited by 
the availability of sufficient surgical samples due to the 
relatively strict criteria we applied for sample selection 
(including only metastases removed within 1 year before 
ipilimumab therapy). On the other hand, a strength of 
our analysis is that it was performed on whole sections 
from surgical samples of more than one metastasis in 
most of the patients. This approach reduces the impact 
of intralesional and interlesional heterogeneity which has 
been described for HLA expression level and immune cell 
infiltration in melanoma and other tumor types.21 If addi-
tional studies with a larger number of metastases corrob-
orate our initial observation that analysis of metastases 
from different anatomic sites may yield different results, it 
will be important to take into account this variable when 
correlating HLA class I APM component expression with 
clinical response to ICI.
Author affiliations
1Department of Surgical and Molecular Pathology, National Institute of Oncology, 
Budapest, Hungary
21st Institute of Pathology and Experimental Cancer Research, Semmelweis 
University, Budapest, Hungary
3Department of Oncodermatology, National Institute of Oncology, Budapest, Hungary
4Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary
5Department of Dermatology, Venerology and Oncodermatology, University of Pécs 
Clinical Center, Pécs, Hungary
6Department of Dermatology, University of Debrecen Medical School and Health 
Science Center, Debrecen, Hungary
7Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 
Boston, Massachusetts, USA
Acknowledgements The authors thank Katalin Derecskei and Miklós Kónya 
(National Institute of Oncology, Budapest) for their excellent technical assistance 
and István Gaudi (National Korányi Institute of TB and Pulmonology) for contribution 
to statistical analysis.
Contributors AL and SF conceived the study; AM, EP, TB and AL performed IHC 
evaluation; GL, JO, AV, ZL and GE contributed to sample collection and patient data 
management; SF supervised the project; AL and SF wrote the manuscript.
Funding The study was supported by the National Research, Development and 
Innovation Office grants NKFI K105132, K116295, ANN 128524, and GINOP_2.3.2-






















8 Ladányi A, et al. J Immunother Cancer 2020;8:e000209. doi:10.1136/jitc-2019-000209
Open access 
Competing interests TB has received speaker honoraria and financial support 
for attending symposia from Bristol- Myers Squibb, MSD Sharp & Dohme (MSD), 
Novartis, and Roche. GL is on the advisory board and has received honoraria for 
speaking at conferences as well as financial support for educational programs from 
Bristol- Myers Squibb, GlaxoSmithKline, MSD, Novartis, and Roche. JO has acted 
as a speaker of symposia and consultant for Bristol- Myers Squibb, MSD, Novartis 
and Roche. ZL has received speaker honoraria from Bristol- Myers Squibb, MSD, 
Novartis, and Roche. GE has received speaker honoraria from Bristol- Myers Squibb, 
MSD, and Roche. SF has received a research grant from Merck.
Patient consent for publication Not required.
ethics approval The study followed the Declaration of Helsinki and was approved 
by the Scientific and Ethical Committee of Medical Research Council, Hungary 
(2506-3/2017/EKU). Informed consents from patients were not required by the 
board in case of retrospective studies where it is not possible to obtain consents 
from the majority of patients as in this case where most patients were deceased at 
the time of the study.
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement All data relevant to the study are included in the 
article or uploaded as supplementary information.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
orCId ids
Andrea Ladányi http:// orcid. org/ 0000- 0001- 9304- 8473
Soldano Ferrone http:// orcid. org/ 0000- 0003- 2900- 8834
reFerenCes
 1 Chen DS, Mellman I. Elements of cancer immunity and the cancer- 
immune set point. Nature 2017;541:321–30.
 2 Gide TN, Wilmott JS, Scolyer RA, et al. Primary and acquired 
resistance to immune checkpoint inhibitors in metastatic melanoma. 
Clin Cancer Res 2018;24:1260–70.
 3 Gnjatic S, Bronte V, Brunet LR, et al. Identifying baseline immune- 
related biomarkers to predict clinical outcome of immunotherapy. J 
Immunother Cancer 2017;5:44.
 4 Gajewski TF, Woo S- R, Zha Y, et al. Cancer immunotherapy 
strategies based on overcoming barriers within the tumor 
microenvironment. Curr Opin Immunol 2013;25:268–76.
 5 Marincola FM, Jaffee EM, Hicklin DJ, et al. Escape of human solid 
tumors from T- cell recognition: molecular mechanisms and functional 
significance. Adv Immunol 2000;74:181–273.
 6 Cai L, Michelakos T, Yamada T, et al. Defective HLA class I antigen 
processing machinery in cancer. Cancer Immunol Immunother 
2018;67:999–1009.
 7 Zaretsky JM, Garcia- Diaz A, Shin DS, et al. Mutations associated 
with acquired resistance to PD-1 blockade in melanoma. N Engl J 
Med 2016;375:819–29.
 8 Gettinger S, Choi J, Hastings K, et al. Impaired HLA class I antigen 
processing and presentation as a mechanism of acquired resistance 
to immune checkpoint inhibitors in lung cancer. Cancer Discov 
2017;7:1420–35.
 9 Sade- Feldman M, Jiao YJ, Chen JH, et al. Resistance to checkpoint 
blockade therapy through inactivation of antigen presentation. Nat 
Commun 2017;8:1136.
 10 Benitez R, Godelaine D, Lopez- Nevot MA, et al. Mutations of the 
beta2- microglobulin gene result in a lack of HLA class I molecules 
on melanoma cells of two patients immunized with MAGE peptides. 
Tissue Antigens 1998;52:520–9.
 11 Campoli M, Ferrone S. HLA antigen changes in malignant cells: 
epigenetic mechanisms and biologic significance. Oncogene 
2008;27:5869–85.
 12 Rodig SJ, Gusenleitner D, Jackson DG, et al. MHC proteins confer 
differential sensitivity to CTLA-4 and PD-1 blockade in untreated 
metastatic melanoma. Sci Transl Med 2018;10:eaar3342.
 13 Johnson DB, Estrada MV, Salgado R, et al. Melanoma- specific 
MHC- II expression represents a tumour- autonomous phenotype 
and predicts response to anti- PD-1/PD- L1 therapy. Nat Commun 
2016;7:10582.
 14 Balatoni T, Mohos A, Papp E, et al. Tumor- Infiltrating immune cells as 
potential biomarkers predicting response to treatment and survival 
in patients with metastatic melanoma receiving ipilimumab therapy. 
Cancer Immunol Immunother 2018;67:141–51.
 15 Pellegrino MA, Ng AK, Russo C, et al. Heterogeneous distribution of 
the determinants defined by monoclonal antibodies on HLA- A and B 
antigens bearing molecules. Transplantation 1982;34:18–23.
 16 Stam NJ, Vroom TM, Peters PJ, et al. HLA- A- and HLA- B- specific 
monoclonal antibodies reactive with free heavy chains in Western 
blots, in formalin- fixed, paraffin- embedded tissue sections and in 
cryo- immuno- electron microscopy. Int Immunol 1990;2:113–25.
 17 Temponi M, Kekish U, Hamby CV, et al. Characterization of anti- HLA 
class II monoclonal antibody LGII-612.14 reacting with formalin fixed 
tissues. J Immunol Methods 1993;161:239–56.
 18 Sul J, Blumenthal GM, Jiang X, et al. FDA approval summary: 
pembrolizumab for the treatment of patients with metastatic non- 
small cell lung cancer whose tumors express programmed death- 
ligand 1. Oncologist 2016;21:643–50.
 19 Oliver AJ, Lau PKH, Unsworth AS, et al. Tissue- dependent tumor 
microenvironments and their impact on immunotherapy responses. 
Front Immunol 2018;9:70.
 20 Jiménez- Sánchez A, Memon D, Pourpe S, et al. Heterogeneous 
tumor- immune microenvironments among differentially growing 
metastases in an ovarian cancer patient. Cell 2017;170:927–38.
 21 Ladányi A, Tímár J. Immunologic and immunogenomic aspects of 
tumor progression. Semin Cancer Biol 2020;60:249–61.
 22 Erdag G, Schaefer JT, Smolkin ME, et al. Immunotype and 
immunohistologic characteristics of tumor- infiltrating immune cells 
are associated with clinical outcome in metastatic melanoma. Cancer 
Res 2012;72:1070–80.
 23 Bartlett EK, Fetsch PA, Filie AC, et al. Human melanoma metastases 
demonstrate nonstochastic site- specific antigen heterogeneity that 
correlates with T- cell infiltration. Clin Cancer Res 2014;20:2607–16.
 24 Hegde PS, Karanikas V, Evers S. The where, the when, and the how 
of immune monitoring for cancer immunotherapies in the era of 
checkpoint inhibition. Clin Cancer Res 2016;22:1865–74.
 25 Lu S, Stein JE, Rimm DL, et al. Comparison of biomarker modalities 
for predicting response to PD-1/PD- L1 checkpoint blockade: a 
systematic review and meta- analysis. JAMA Oncol 2019;5:1195–204.
 26 Balatoni T, Mohos A, Papp E, et al. Different impact of immune cell 
infiltration and HLA class I expression in lymph node vs. cutaneous/
subcutaneous metastases as predictive markers in melanoma 

















ancer: first published as 10.1136/jitc-2019-000209 on 17 June 2020. D
ow
nloaded from
 
